^
    Back
    Association details:
    Biomarker:KDR C482R
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    Votrient (pazopanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Onco Targets Ther
    Title:

    A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

    Published date:
    05/07/2021
    Excerpt:
    This is a single institution, open-label, phase I dose-escalation study in patients with advanced malignancies (NCT 01548144)....Among other patients with PR as best response to therapy, we had a clear cell renal cancer patient (−32%, PR) with a Kinase Insert Domain Receptor (KDR) p.C482R mutation previously treated with multiple lines of therapy including pazopanib monotherapy for a year (best response on monotherapy was SD).
    DOI:
    10.2147/OTT.S291801
    Trial ID:
    NCT01548144